Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by blocking muscarinic receptors (M3) in the airways, leading to bronchodilation and improved airflow. Umeclidinium is used once daily as a dry powder inhaler for long-term COPD symptom management.
Parent: Umeclidinium Bromide
Parent: Umeclidinium Bromide
Parent: Umeclidinium Bromide
Parent: Umeclidinium Bromide
Parent: Umeclidinium Bromide
Impurities in Umeclidinium Bromide can arise due to chemical synthesis, degradation, or improper storage conditions. Regulatory agencies such as the FDA, EMA, and ICH enforce impurity limits to ensure drug safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Umeclidinium bromide helps relax the muscles in the airways, making it easier to breathe for patients with chronic obstructive pulmonary disease (COPD). It:
Umeclidinium is a LAMA (Long-Acting Muscarinic Antagonist), not a LABA (Long-Acting Beta Agonist).
No, Umeclidinium does not contain steroids. It is a bronchodilator used to relax airway muscles and improve breathing. However, it is sometimes combined with steroids (e.g., Fluticasone) in combination inhalers for severe COPD management.
Umeclidinium belongs to the anticholinergic drug class, specifically:
